Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit 

Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 7th Cannabinoid-Derived Drug Development Summit, taking place November 18-20, 2024, in Boston. Professor Saoirse O'Sullivan, VP of Translational Sciences, will present key data from three development programs:

1. FABP5 Inhibitors as Novel Therapeutics (ART26.12)
2. ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia
3. ART12.11: A Novel Cannabidiol Cocrystal comparable to Epidiolex®

The presentations aim to explore business development and collaboration opportunities, showcasing how lipid modification can address serious medical conditions with treatment options.

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA.

Key data from Artelo’s development programs will be highlighted in three separate sessions titled:

• Fatty Acid-Binding Protein 5 (FABP5) Inhibitors as Novel Therapeutics (featuring ART26.12)
• ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia
• ART12.11: A Novel Cannabidiol Cocrystal Demonstrating a Pharmacokinetic Profile Comparable to Epidiolex® in Rats
  

“We are delighted to share the results of our work from three innovative approaches to endocannabinoid and lipid modification,” said Professor O’Sullivan. “These presentations provide an opportunity to explore business development and collaboration with academic and industrial researchers. Our clinical and preclinical pipeline exemplifies how lipid modification can lead to the development of distinct and differentiated product candidates addressing serious medical conditions with limited treatment options.”

For event registration, please visit: https://cannabinoid-derived-drug-development.com/take-part/register/

About ART27.13
ART27.13 is a highly potent, peripherally restricted new chemical entity, targeting CB₁ and CB₂ receptors, with the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer cachexia patients. Originally developed by AstraZeneca plc, ART27.13 has been in clinical studies with over 250 subjects. A statistically significant and dose-dependent increase in body weight was observed in patients with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Having completed a Phase 1 study in cancer patients where ART27.13 demonstrated an excellent safety profile, Artelo is now advancing it in the CAReS trial as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Currently, there is no FDA-approved treatment for cancer anorexia cachexia syndrome.

About ART26.12
ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) is the first selective FABP5 inhibitor to be cleared by FDA to initiate first-in-human studies. ART26.12 is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy (CIPN). Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. Beyond ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.

About ART12.11
ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Superior pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

FAQ

What three drug programs will Artelo Biosciences present at the 2024 Cannabinoid Summit?

Artelo will present data on ART26.12 (FABP5 Inhibitors), ART27.13 (CB1/CB2 Agonist for Cancer Cachexia), and ART12.11 (Cannabidiol Cocrystal) at the summit.

When and where is Artelo Biosciences presenting at the Cannabinoid Drug Development Summit?

Artelo is presenting at the Wyndham Beacon Hill Hotel in Boston, MA, from November 18-20, 2024.

How does ART12.11 compare to Epidiolex according to Artelo's presentation?

According to the presentation, ART12.11, a novel cannabidiol cocrystal, demonstrates a pharmacokinetic profile comparable to Epidiolex® in rats.

What is the purpose of Artelo's ART27.13 drug candidate?

ART27.13 is being developed as a peripherally selective CB1/CB2 agonist specifically for treating cancer cachexia.